AstraZeneca stock rises on lung cancer trial news

AstraZeneca plc stock gained after phase III lung cancer updates and a separate trial stop on August 17, 2026, with U.S.-listed shares last seen at $156.72 and market value at $244.09 billion.

The move followed reports that two late-stage studies pointed to stronger oncology data, while another experimental program was halted after it failed to clear a key bar versus existing treatment.

Trial data drives the move

The latest oncology readouts matter because one study met its primary endpoint in first-line non-small cell lung cancer, while another update pointed to progress in the same cancer area. A third program, volrustomig, was stopped after it did not look strong enough against standard therapy.

Those details gave the shares a clear catalyst on a day when the stock also traded in a narrow intraday range of $156.58 to $157.00. The one-day change was +0.87% in the most recent market snapshot.

What the numbers say

The market data line is firm: $156.72, a $244.09 billion market cap, and an intraday band of $156.58 to $157.00. That backdrop matters because the stock was already trading close to its recent high of $157.32.

For comparison, the latest visible market snapshot also showed the shares up 0.87% on the session, which is a sharper tone than the broad market often shows on a single catalyst-led move. The combination of a positive phase III result and a program stop makes the reaction easy to read.

More on AstraZeneca stock

Oncology stays central

AstraZeneca's oncology franchise remains anchored by antibody-drug-conjugate and lung-cancer work, with Enhertu named in the latest trial coverage. That keeps the commercial story tied to late-stage data rather than broad sector sentiment.

Investors will also note that the most recent reporting cycle cited annual revenue guidance of $80 billion by 2030 in earlier company commentary, a scale target that frames how important the lung-cancer portfolio is to the longer-term thesis.

Price level to watch

AstraZeneca stock last traded at $156.72 on August 17, 2026, with the session ending near the top of its intraday range. The share price sat just under the $157.32 recent high in the same snapshot.

Fact box

Company: AstraZeneca plc
ISIN: US6549022043
Ticker: AZN
Exchange: Nasdaq
Price (as of August 17, 2026, 12:58 p.m. ET): $156.72 USD
Market cap: $244.09 billion (as of August 17, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: FTSE 100